Literature DB >> 11518490

What to measure in autism drug trials.

B Roseman, E Schneider, D Crimmins, H Bostwick, P Visintainer, P A Jaskow, P Accardo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11518490     DOI： 10.1023/a:1017339106682

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN： 0162-3257


× No keyword cloud information.
  3 in total

1.  Secretin and autism: a two-part clinical investigation.

Authors:  M G Chez; C P Buchanan; B T Bagan; M S Hammer; K S McCarthy; I Ovrutskaya; C V Nowinski; Z S Cohen
Journal:  J Autism Dev Disord       Date:  2000-04

2.  Improved social and language skills after secretin administration in patients with autistic spectrum disorders.

Authors:  K Horvath; G Stefanatos; K N Sokolski; R Wachtel; L Nabors; J T Tildon
Journal:  J Assoc Acad Minor Phys       Date:  1998

3.  Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.

Authors:  A D Sandler; K A Sutton; J DeWeese; M A Girardi; V Sheppard; J W Bodfish
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245
  3 in total
  2 in total

1.  Measurement tools and target symptoms/skills used to assess treatment response for individuals with autism spectrum disorder.

Authors:  Erin Elizabeth Bolte; Joshua John Diehl
Journal:  J Autism Dev Disord       Date:  2013-11

2.  Role of donepezil in autism: its conduciveness in psychopharmacotherapy.

Authors:  Rohit Kant Srivastava; Medhavi Agarwal; Ashish Pundhir
Journal:  Case Rep Psychiatry       Date:  2011-11-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.